While cancer immunotherapies are definitely becoming more de rigeur these days, that doesn’t mean that good old fashioned targeted therapies have been universally abandoned or forgotten, far from it.

Making strategic choices about how to differentiate targeted therapies is never easy

At recent meetings this year, my attention was caught by one target in particular, and despite its chequered history it seems to be making a comeback of sorts thanks to a more focused and tailored approach to therapy.

There is unlikely to be one panacea for everything, but what about going back to basics and matching patients to appropriate therapy based on the underlying biology and what the patiemt’s tumour is telling us? We should have more success doing that theoretically – is that actually the case in practice?

To illustrate this, we have a few examples to share from one particular niche in oncology that readers may find interesting and useful…

To learn more from our latest analysis and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

Posted by